Where does Zymeworks's income statement data come from?

Every line is extracted from Zymeworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Zymeworks ZYME Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$81.26M-13.0%	$105.97M+38.9%	$134.48M+116%	$122.87M+95.9%	$93.38M+85.1%
Research and development	——	——	$142.83M+16.0%	$143.6M+20.2%	$138.32M+6.6%
General and administrative	$59.6M-4.9%	$61.51M0.0%	$62.27M+3.5%	$61.97M-2.0%	$62.7M-9.5%
Compensation and benefits	——	——	——	——	$20.64M+121%
Occupancy and equipment	$4.35M+55.2%	$3.36M+37.1%	$3.03M+0.8%	$3.05M-56.1%	$2.8M-60.3%
Depreciation and amortization	——	——	——	——	$5.41M+98.6%
Goodwill impairment	——	——	——	——	——
Other operating expenses	$10.09M-43.2%	$12.8M-37.6%	$14.55M-28.3%	$15.29M-28.5%	$17.75M-14.3%
Total costs & expenses	$195.32M-10.5%	$198.51M-7.0%	$205.1M+2.3%	$205.58M+2.8%	$218.31M+9.7%
Operating income	-$114.05M+8.7%	-$92.55M+32.5%	-$70.61M+48.9%	-$82.71M+39.8%	-$124.92M+15.9%
Operating margin	-140.4%-6.6pp	-87.3%+92.3pp	-52.5%+170pp	-67.3%+152pp	-133.8%+161pp
Interest expense	$12.64M-27.5%	$13.35M-33.0%	$14.46M-30.8%	$15.72M-25.7%	$17.45M-16.2%
Other income (expense), net	-$488K-261%	-$559K-200%	$87K+114%	-$432K-296%	$303K+394%
Income before income taxes	-$103.97M+3.0%	-$79.75M+31.6%	-$56.07M+52.5%	-$67.42M+41.9%	-$107.17M+16.2%
Income tax expense	——	——	$7.36M+269%	$6.25M+280%	$6.51M+445%
Net income	-$102.66M+9.7%	-$81.13M+33.9%	-$63.43M+44.2%	-$73.68M+34.5%	-$113.68M+9.8%
Net margin	-126.3%-4.6pp	-76.6%+84.2pp	-47.2%+136pp	-60%+119pp	-121.7%+128pp
Diluted earnings per share	-$1.37+8.7%	-$1.08+33.3%	-$0.85+43.0%	-$0.98+35.1%	-$1.50+15.7%
Basic earnings per share	-$1.37+8.7%	-$1.08+33.3%	-$0.85+43.0%	-$0.98+35.1%	-$1.50+15.7%
Weighted-average shares, diluted	303.3M-0.1%	303.8M-0.3%	304.3M+2.2%	304.6M+4.3%	303.7M+7.3%
Weighted-average shares, basic	301.2M-0.8%	301.7M-1.0%	302.1M+1.5%	302.5M+3.6%	303.5M+7.3%
Interest Income (Expense), Nonoperating	$12.64M-27.5%	$13.35M-33.0%	$14.46M-30.8%	$15.72M-25.7%	$17.45M-16.2%
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation	——	——	——	——	——
Share-based compensation expense related to employee stock plans	$27.16M+35.3%	$27.07M+61.9%	$23.3M+56.1%	$20.96M+54.3%	$20.08M+113%
Amortization Of Financing Costs	——	——	——	——	——
Amortization of capitalized software and acquired intangible assets	$2.62M-51.7%	$4.06M-9.8%	$5.87M+85.4%	$6.21M+117%	$5.41M+98.6%
Amortization of issuance costs	——	——	——	——	——
Capital investments accrued but not yet paid	——	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$102.82M+8.5%	-$80.26M+34.8%	-$63.48M+43.0%	-$72.11M+36.0%	-$112.36M+12.1%
Concentration Risk Credit Risk Financial Instrument Maximum Exposure	——	$4.64M-91.7%	$17.43M—	$30.23M—	$43.02M—
Conversion Of Stock Amount Converted1	——	——	——	——	——
Federal	——	-$482K—	——	——	——
Foreign	——	$898K—	——	——	——
Current State And Local Tax Expense Benefit	——	$15K—	——	——	——
Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Maturity, Allocated and Single Maturity Date, After Year One Through Four	——	——	——	——	——
Debt securities, unrealized gain	——	——	——	——	$153.5K-47.9%
Gain (loss) on available-for-sale debt securities	——	——	——	——	$1.03M+200%
Federal	——	$845K—	——	——	——
Deferred Foreign Income Tax Expense Benefit	——	$100K—	——	——	——
Deferred taxes	——	$945K+36.8%	$881.5K+168%	$818K+2,579%	$754.5K+291%
State	——	$0—	——	——	——
Depreciation	$3.65M-11.1%	$3.67M-12.4%	$3.77M-20.3%	$3.9M-36.0%	$4.11M-40.8%
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	——	——	——	$185K—
Effective tax rates	——	-$0.02—	——	——	——
Income taxes at U.S. statutory rate of 21%	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change In Recognition And Measurement Of Tax Positions, Amount	——	——	——	——	——
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount	——	$0—	——	——	——
Other	——	——	——	——	——
Effective Income Tax Rate Reconciliation, FDII, Amount	——	-$2.01M—	——	——	——
Effective Income Tax Rate Reconciliation, FDII, Percent	——	——	——	——	——
Nontaxable or nondeductible items	——	——	——	——	——
State income taxes – net of federal income tax benefit	——	——	——	——	——
Changes in unrecognized tax benefits	——	——	——	——	——
Adjustment for change in fair value of liability classified stock options	——	——	——	——	$54K+122%
Finance Lease Right Of Use Asset Amortization	——	——	——	——	——
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	——	——	——	——	$1.16M—
Goodwill impairment losses	——	——	——	——	——
Income Loss From Continuing Operations Before Income Taxes Domestic	——	-$16.81M—	——	——	——
Income Loss From Continuing Operations Before Income Taxes Foreign	——	-$62.95M—	——	——	——
Federal taxes	——	$213K—	——	——	——
State taxes	——	$17K—	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	——	——	——	——
Income Tax Reconciliation Change In Enacted Tax Rate	——	$0—	——	——	——
Income Tax Reconciliation Foreign Income Tax Rate Differential	——	——	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	-$16.75M+31.5%	-$18.68M+24.1%	-$20.61M+16.8%	-$22.54M+9.5%
Nontaxable or Nondeductible items	——	$122K-98.8%	$2.72M-68.2%	$5.32M-19.5%	$7.91M+70.2%
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	——	——	——	——
Income Tax Reconciliation Prior Year Income Taxes	——	——	——	——	——
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	$15K—	——	——	——
Changes in unrecognized tax benefits	——	$97K—	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	——	——	——	——
Income Taxes Paid, Net	$1.21M-66.1%	$1.35M-57.5%	$4.21M+1,562%	$3.66M+1,840%	$3.57M+2,782%
Accounts payable and other current liabilities	——	——	——	-$14.46M—	——
Increase (Decrease) in Accounts Receivable	——	——	——	——	——
Increase Decrease In Accrued Income Taxes Payable	-$60K+96.5%	-$45K+97.3%	-$1.06M-185%	-$1.83M-336%	-$1.73M-270%
Increase (decrease) in contract liabilities and current deferred income	-$21.42M—	-$23.17M—	——	——	——
Increase (Decrease) in Deferred Income Taxes	——	——	——	——	-$319K-140%
Operating lease liabilities	——	——	——	——	-$8.09M-109%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Adjustment for dilutive effect of liability classified stock options (in shares)	——	——	——	——	119.6K+225%
Interest Expense And Amortization Related to Sale of Future Royalties	——	——	——	——	——
Interest expense related to sale of future royalties	——	——	——	——	——
Issuance costs related to sale of future royalties not yet paid	——	——	——	——	——
Lease Cost	$6.54M+8.9%	$5.61M+3.0%	$5.24M-12.2%	$5.14M-47.5%	$6M-31.2%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$158.91M+848%	-$18.56M+9.2%	-$8.46M-122%	-$20.97M-138%	-$21.25M-126%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	$84.44M—	$26.66M—	——	——	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$75.32M+0.6%	-$33.01M+70.0%	-$64.26M—	-$38.73M—	-$75.79M—
Non-cash interest expense related to sale of royalties	——	——	——	——	——
Number of operating segments	——	1—	——	——	——
Number of reportable segments	——	——	——	——	——
Number of reporting units	——	10.0%	1—	1—	1—
Lease impairment	——	$316K—	——	——	——
Operating Lease Payments	$4.31M+11.7%	$4.27M+2.8%	$4.16M—	$4.05M—	$3.86M—
Operating lease right-of-use assets amortization expense	$4.39M+64.5%	$3.39M+34.9%	$3.15M+6.5%	$2.77M-52.1%	$2.67M-62.2%
Unrealized gains (losses) on available-for-sale debt securities, tax	$0—	$0—	$0—	$0—	$0—
Other comprehensive income/(loss)	-$130K-110%	$902K+358%	-$51K-102%	$1.56M+1,819%	$1.32M+174%
Net unrealized gains (losses) on securities still held	-$130K-110%	$902K+358%	-$51K-102%	$1.56M+1,819%	$1.32M+174%
Other income, net	$10.09M-43.2%	$12.8M-37.6%	$14.55M-28.3%	$15.29M-28.5%	$17.75M-14.3%
Payments for Repurchase of Common Stock	——	——	——	——	——
Payments for Transaction Costs Related to Sale of Future Royalties	——	——	——	——	——
Payments to Acquire Intangible Assets	$509K-45.2%	$831K-22.7%	$692K-72.0%	$795K-69.1%	$928K-55.2%
Payments to Acquire Marketable Securities	——	——	——	——	$251.27M-42.6%
Payments to Acquire Property, Plant, and Equipment	$1.72M-5.5%	$1.52M-23.6%	$1.25M-38.3%	$1.74M-15.6%	$1.82M-19.8%
Issuance of common stock through employee stock purchase plan	——	——	——	——	——
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options	$24.85M+215%	$16.9M+90.9%	$10.86M+22.9%	$8.14M+63.6%	$7.89M+50.7%
Proceeds from maturities of marketable securities	——	——	——	——	$312.27M-14.6%
Proceeds From Sale of Future Royalties	——	——	——	——	——
Cash received from option exercises	——	——	——	——	$7.89M+50.7%
Research and development expense	$135.72M-1.9%	$137M+1.8%	$142.83M+16.0%	$143.6M+20.2%	$138.32M+6.6%
Revenue From Contract With Customer Excluding Assessed Tax	$81.26M-13.0%	$105.97M+38.9%	$134.48M+116%	$122.87M+95.9%	$93.38M+85.1%
Royalty Payments	——	——	——	——	——
Issuance costs	——	——	——	——	——
Stock-based compensation	$28.57M+38.4%	$28.03M+57.6%	$24.21M+50.0%	$21.96M+62.4%	$20.64M+121%
Weighted-average grant date fair value of stock options (in dollars per share)	——	——	——	——	——
Granted (in shares)	——	——	——	——	——
Risk-free rate	——	——	——	——	——
Percent of share based award available for grant in succeeding calendar year	——	——	——	——	——
Weighted-average volatility	——	——	——	——	——
Weighted-average dividend yield	——	——	——	——	——
Intrinsic value of stock options exercised	——	$14.15M+531%	$11.17M+497%	$8.2M+446%	$5.22M+362%
Unamortized compensation expense related to unvested options	——	——	——	——	——
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value	——	——	——	——	——
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares	——	——	——	——	——
Issue of shares upon vesting of restricted stock units (in shares)	——	——	——	——	——
Stock issued for employee stock purchase plan	——	——	——	——	——
Issuance of vested restricted stock units	——	——	——	——	——
Stock Issued During Period, Value, Stock Options Exercised	$25.69M+221%	$17.75M+93.3%	$11.6M+27.3%	$8.25M+57.5%	$8M+44.7%
Value of shares repurchased	——	——	——	——	——
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions	——	$0—	$0—	$0—	$0—
Unrecognized tax benefits, settlements	——	$0—	$0—	$0—	$0—
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions	——	$97K+155%	$82.25K+157%	$67.5K+160%	$52.75K+164%
Additions for tax positions of prior years	——	$2.36M—	$1.77M—	$1.18M—	$591K—
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations	——	$0—	$0—	$0—	$0—
Variable Lease Cost	$2.19M+1.2%	$2.26M+14.6%	$2.21M+14.8%	$2.09M+14.6%	$2.17M+29.8%
EBIT	-$114.05M+8.7%	-$92.55M+32.5%	-$70.61M+48.9%	-$82.71M+39.8%	-$124.92M+15.9%
EBITDA	-$107.79M+6.6%	-$84.82M+34.0%	-$60.97M+53.2%	-$72.61M+43.5%	-$115.4M+16.9%
EBITDA	-$107.79M+6.6%	-$84.82M+34.0%	-$60.97M+53.2%	-$72.61M+43.5%	-$115.4M+16.9%
EBITDA margin	-132.6%-9.1pp	-80%+88.3pp	-45.3%+164pp	-59.1%+146pp	-123.6%+152pp
EBIT	-$114.05M+8.7%	-$92.55M+32.5%	-$70.61M+48.9%	-$82.71M+39.8%	-$124.92M+15.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Zymeworks's income statement data come from?: Every line is extracted from Zymeworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.